STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

VIVO MERIDIAN BIOSCIENCE INCO StockScouter® Report

5

StockScouter® Score

MERIDIAN BIOSCIENCE INCO, a small cap growth company in the healthcare sector, is expected to slightly outperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
  • Two or more executives, directors or major shareholders purchased a large number of shares recently. Very positive

 

Concerns

  • One or more analysts has significantly decreased quarterly earnings estimates for VIVO. Negative
  • The multi-period measure of relative price change and consistency is well below average. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be in favor, growth stocks will be in favor, and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 60% done.
Progress: 80% done.
Low
High

Core Model Grades

C
A
C
F

Previous Ratings

4
5
7